CXL Ophthalmics Announces New Name and Vision as Epion Therapeutics
CXL Ophthalmics, Inc., a leading innovator in corneal disease treatments, is pleased to announce its new name as Epion Therapeutics, Inc.
- CXL Ophthalmics, Inc., a leading innovator in corneal disease treatments, is pleased to announce its new name as Epion Therapeutics, Inc.
- This vision and strategic direction precede enrollment in Epion’s Phase 3 Trials of the EpiSmart™ System.
- Keratoconus is a corneal disorder characterized by thinning and conical protrusion of the cornea, causing distorted vision.
- Epion Therapeutics is pioneering early intervention with the goal of treating patients upon diagnosis, eliminating the requirement to wait for disease progression,” said Michael Belin, Chief Medical Officer at Epion.